We are live on ! Find out more
ANVS icon

Annovis Bio
ANVS

24 hedge funds and large institutions have $11.9M invested in Annovis Bio in 2022 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 8 increasing their positions, 7 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

14% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 7

2.88% less ownership

Funds ownership: 13.78% → 10.9% (-2.9%)

25% less funds holding

Funds holding: 32 → 24 (-8)

39% less capital invested

Capital invested by funds: $19.6M → $11.9M (-$7.75M)

80% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 10

Holders
24
Holders Change
-8
Holders Change %
-25%
% of All Funds
0.38%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
8
Reduced
7
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$192K
2
Renaissance Technologies
Renaissance Technologies
New York
+$183K
3
SIAP
Sterling Investment Advisors (Pennsylvania)
Pennsylvania
+$65K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$15.6K
5
EL
Essex LLC
Illinois
+$14.4K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$1.04M
2
Two Sigma Investments
Two Sigma Investments
New York
-$910K
3
Morgan Stanley
Morgan Stanley
New York
-$649K
4
Voloridge Investment Management
Voloridge Investment Management
Florida
-$406K
5
BAM
Blueshift Asset Management
New Jersey
-$289K

ANVS Hedge Fund Activity: Q1 2022 in Review

24 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Annovis Bio (ANVS) for Q1 2022, worth a combined $11.9M — down 39% from $19.6M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of ANVS and 2 opened new positions — a net loss of 8 holders — while 7 trimmed existing stakes and 8 added.

The largest buyer was Vanguard Group, adding an estimated $192K. The largest seller was Citadel Advisors, exiting entirely with an estimated $1.04M sold.

  • 24 institutional investors held Annovis Bio (ANVS) as of Q1 2022, down from 32 in Q4 2021.
  • Funds reported $11.9M of Annovis Bio stock for Q1 2022, down 39% quarter-over-quarter.
  • 2 funds opened new Annovis Bio positions in Q1 2022 and 10 closed out, a net change of -8 holders.
  • The largest Annovis Bio buyer in Q1 2022 was Vanguard Group, an estimated $192K added.
  • The largest Annovis Bio seller in Q1 2022 was Citadel Advisors, an estimated $1.04M sold.

Based on aggregated 13F filings for Q1 2022.